Summary – Week 05 (ending 03 February 2019)

- During week 05 influenza continued to circulate in the community with activity indicators at Low intensity.
- The impact of flu on healthcare services is at High impact for hospitalisations and ICU/HDU influenza admissions.
- Influenza A(H1N1)pdm09 is the dominant circulating subtype. The Department of Health & Social Care has issued an alert on the prescription of antiviral medicines by GPs.

Community
- Seventy-three acute respiratory outbreaks have been reported in the past 7 days. Forty-one outbreaks were reported from care homes where 21 tested positive for influenza A(not subtyped) and 2 for RSV. Eight outbreaks were reported from hospitals where 6 tested positive for influenza A(not subtyped). Twenty-one outbreaks were reported from schools where 2 were positive for influenza A(H1N1)pdm09 and 8 were positive for influenza A(not subtyped). The remaining 3 outbreaks were reported from the Other settings category where 1 tested positive for influenza A(not subtyped).

Primary Care
- The rate of influenza-like illness (ILI) was at Low intensity levels. The overall weekly ILI GP consultation rate was 19.7 per 100,000 registered population in participating GP practices for England, this is a slight increase from 17.5 per 100,000 in week 04 2018.
- In the devolved administrations, ILI rates were Below Baseline threshold levels for Northern Ireland and were at Low intensity levels for Scotland and Medium intensity levels for Wales.

Secondary Care
- Hospitalisation rate observed was at High impact levels, with a rate of 5.99 per 100,000 trust catchment population for England (22 NHS Trusts), this is similar to 5.92 per 100,000 in week 04.
- ICU/HDU admission rate observed was at High impact levels, with a rate of 0.56 per 100,000 trust catchment population for England (135/143 NHS Trusts), this is similar to 0.56 per 100,000 in week 04.
- There were 6 new influenza admissions (5 influenza A(H1N1)pdm09 and 1 influenza A(unknown subtype)) reported from the 6 Severe Respiratory Failure centres in the UK.

All-cause mortality
- In week 05 2019, no statistically significant excess all-cause mortality by week of death was seen overall and by age group in England. In the devolved administrations, no statistically significant excess all-cause mortality for all ages was observed in Wales in week 05 and in Scotland in week 03 2019.

Microbiological surveillance
- Primary care: 56 sample tested positive for influenza (48 influenza A(H1N1)pdm09, 5 influenza A(H3) and 3 influenza A(not subtyped)) with a positivity of 50.5% through the UK GP sentinel swabbing schemes.
- Secondary care: Influenza percent positivity was 25.6%, Above Baseline threshold level, this is similar to 24.5% in week 04. There were 810 detections recorded through the DataMart scheme (397 influenza A(H1N1)pdm09, 144 influenza A(H3), 268 influenza A(not subtyped) and 1 influenza B).

Vaccination
- Weekly uptake: Up to week 04 2019, in 97.4% of GP practices the provisional proportion of people in England who had received the 2018/19 influenza vaccine in targeted groups was: 46.7% in under 65 years in a clinical risk group, 44.8% in pregnant women and 71.2% in 65+ year olds. In 97.5% of GP practices reporting for the childhood collection the provisional proportion vaccinated was: 43.0% in 2 year olds and 45.0% in 3 year olds.
- Provisional data from the third monthly collection of influenza vaccine uptake by frontline healthcare workers show 65.8% were vaccinated by 31 December 2018, compared to 63.9% vaccinated in the previous season by 31 December 2017.
- Provisional data from the third monthly collection of influenza vaccine uptake for children of school years reception to year 5 shows 58.6% in school year reception age, 62.2% in school year 1 age, 60.3% in school year 2 age, 59.1% in school year 3 age, 56.9% in school year 4 age and 55.1% in school year 5 age were vaccinated by 31 December 2018.

International situation
- In the temperate zone of the Northern hemisphere, influenza activity continued to increase with influenza A(H1N1)pdm09 predominating overall. In the temperate zones of the Southern hemisphere, influenza activity returned to inter-seasonal levels. Worldwide, seasonal influenza subtype A viruses accounted for the majority of detections.
Seventy-three new acute respiratory outbreaks were reported in the past 7 days.

- **Acute respiratory disease outbreaks**
  - Seventy-three new acute respiratory outbreaks have been reported in the past 7 days. Forty-one outbreaks were reported from care homes where 21 tested positive for influenza A (not subtyped) and 2 for RSV. Eight outbreaks were reported from hospitals where 6 tested positive for influenza A (not subtyped). Twenty-one outbreaks were reported from schools where 2 were positive for influenza A (H1N1)pdm09 and 8 were positive for influenza A (not subtyped). The remaining 3 outbreaks were reported from the Other settings category where 1 tested positive for influenza A (not subtyped).
  - Outbreaks should be recorded on HPZone and reported to the local Health Protection Teams and respscidsc@phe.gov.uk

- **Medical Officers of Schools Association (MOSA) & PHE surveillance scheme**
  - Boarding schools in England within the MOSA network are recruited each season to report various respiratory related illnesses including influenza like illnesses (ILI). For the 2018/19 season, 21 MOSA schools have agreed to participate in the scheme, including a total of 6,530 boarders.
  - The overall rate (all boarders) for week 05 was 1.6 per 1,000 boarders compared to 1.4 per 1,000 boarders in week 04.
  - Since week 40, there have been 13 outbreaks reported from 7 MOSA schools, with a total of 44 ILI cases identified. Of the 11 outbreaks, 2 outbreaks have tested positive for influenza A (H1N1)pdm09 and 1 outbreak has tested positive for influenza B.
  - If you are a MOSA school and would like to participate in this scheme, please email mosa@phe.gov.uk for more information.

- **FluSurvey**
  - Internet-based surveillance of influenza-like illness in the general population is undertaken through FluSurvey. A project run by PHE to monitor ILI activity in the community.
  - The overall ILI rate (all age groups) for week 05 2019 was 38.5 per 1,000 (61/1,584 people reported at least 1 ILI) (Figure 3) compared to 31.4 per 1,000 in the previous week, with the highest rate seen in the 22-44 year olds (56.3 per 1,000).
  - If you would like to become a participant of the FluSurvey project please do so by visiting the https://flusurvey.net/en/accounts/register/ website for more information.
In week 05, the overall weekly influenza-like illness (ILI) GP consultation rate increased slightly from the previous week but remained at low intensity levels in England. In the devolved administrations, ILI rates increased with Scotland at low intensity levels and Wales at medium intensity levels.

- GP ILI consultations in the UK

**RCGP (England)**
- The weekly ILI consultation rate through the RCGP surveillance was at 19.7 per 100,000 registered population in participating GP practices in week 05 2019, this is a slight increase from 17.5 per 100,000 in week 04. This is above the baseline threshold (13.1 per 100,000) (Figure 4*).
- By age group, the highest rates were seen in 45-64 year olds (24.3 per 100,000) and in 15-44 year olds (22.9 per 100,000).


**UK**
- In week 05, overall weekly ILI consultation rates across all countries of the UK have increased and were above their respective baseline thresholds for England and Scotland at low activity levels and Wales at medium activity level. In Northern Ireland ILI rate remains below baseline threshold levels (Table 1).
- By age group, the highest rates were seen in the 45-64 year olds in Scotland and Northern Ireland (47.2 per 100,000 and 18.4 per 100,000 respectively) and in the 5-14 year olds in Wales (24.2 per 100,000).

**GP In Hours Syndromic Surveillance System (England)**
- The weekly ILI consultation rate through the GP In Hours Syndromic Surveillance system is at 15.0 per 100,000 in week 05 2019 (Figure 5).
- During week 05, there were small increases in influenza-like illness (ILI) seen in ED attendances, GPHI and GPOOH. There were further small increases in NHS 111 cold/flu calls. GPHI saw an increase in upper respiratory tract consultations, mainly in children aged <15 years old, but remained below expected levels.
- Figure 5 represents a map of GP ILI consultation rates in week 05 across England by PHE centres, with influenza-like illness surveillance MEM thresholds applied.

ILI consultation rates presented for each uLTA on the map should be interpreted in context of regional and national ILI activity; as MEM thresholds are calculated (based on previous influenza seasons from 2012/13 onwards) separately for each of the nine PHE centres and uLTA rates are then compared to Centre-level thresholds only, therefore uLTAs with higher background rates than the Centre may appear to have higher ILI activity.
- For further information, please see the syndromic surveillance webpage.
In week 05 2019, there were 583 hospitalised confirmed influenza cases (238 influenza A(H1N1)pdm09, 56 influenza A(H3N2), 288 influenza A(unknown subtype) and 1 influenza B) reported through the USISS sentinel hospital network across England (22 NHS Trusts). There were 285 new admissions to ICU/HDU with confirmed influenza (75 influenza A(H1N1)pdm09, 10 influenza A(H3N2) and 200 influenza A(unknown subtype)) reported through the USISS mandatory ICU/HDU surveillance scheme across the UK (135/143 NHS Trusts in England).

- In week 05 2019, there were 583 hospitalised laboratory confirmed influenza cases (238 influenza A(H1N1)pdm09, 56 influenza A(H3N2), 288 influenza A(unknown subtype) and 1 influenza B) reported from 22 NHS Trusts across England through the USISS sentinel hospital network, with a rate of 5.92 per 100,000 trust catchment population compared to 5.99 per 100,000 in the previous week (Figures 6 and 7). This is above the baseline impact threshold of 0.89 per 100,000 within the high impact range.

- A total of 2,881 hospitalised confirmed influenza admissions (1,199 influenza A(H1N1)pdm09, 249 influenza A(H3N2), 1,141 influenza A(unknown subtype) and 25 influenza B) and have been reported in the UK since week 40 2018 via the sentinel scheme.

- A total of 2,881 hospitalised confirmed influenza admissions (1,199 influenza A(H1N1)pdm09, 249 influenza A(H3N2), 1,141 influenza A(unknown subtype) and 25 influenza B) and have been reported in the UK since week 40 2018 via the sentinel scheme.

- Number of new admissions and fatal confirmed influenza cases in ICU/HDU (USISS mandatory ICU scheme), UK (week 05)

- In week 05 2019, there were 285 new admissions to ICU/HDU with confirmed influenza (75 influenza A(H1N1)pdm09, 10 influenza A(H3N2) and 200 influenza A(unknown subtype)) reported across the UK (135/143 Trusts in England) through the USISS mandatory ICU scheme. The rate for England (n=270) was 0.56 per 100,000 trust catchment population compared to 0.56 per 100,000 in the previous week (Figures 8 and 9), above the baseline threshold of 0.09 per 100,000 within the high impact range. Twenty-six influenza laboratory-confirmed deaths were reported to have occurred in ICU in week 05 in the UK.

- A total of 1,884 new ICU/HDU admissions (626 influenza A(H1N1)pdm09, 98 influenza A(H3N2), 1,141 influenza A(unknown subtype) and 19 influenza B) and 168 confirmed deaths have been reported in the UK since week 40 2018.

The Moving Epidemic Method (MEM) has been adopted by the European Centre for Disease Prevention and Control to calculate thresholds for ICU/HDU admission rates for the start of influenza activity (based on 6 seasons) in a standardised approach across Europe. For MEM threshold values, please visit: https://www.gov.uk/guidance/sources-of-uk-flu-data-influenza-surveillance-in-the-uk#disease-severity-and-mortality-data
In week 05 2019, no statistically significant excess all-cause mortality by week of death was observed overall and by age group in England, through the EuroMOMO algorithm. In the devolved administrations, no statistically significant excess all-cause mortality for all ages was observed in Wales in week 05 2019 and in Scotland in week 03 2019.

- All-cause death registrations, England and Wales

  - In week 04 2019, an estimated 11,740 all-cause deaths were registered in England and Wales (source: Office for National Statistics). This is a decrease compared to the 11,860 estimated death registrations in week 03 2019.

- Excess all-cause mortality by age group, England, Wales, Scotland and Northern Ireland

  - In week 05 2019 in England, no statistically significant excess mortality by week of death above the upper 2 z-score threshold was seen overall, by age group and sub-nationally (all ages), after correcting ONS disaggregate data for reporting delay with the standardised EuroMOMO algorithm. This data is provisional due to the time delay in registration; numbers may vary from week to week.

  - In the devolved administrations, no statistically significant excess all-cause mortality for all ages was observed in Wales in week 05 2019 and in Scotland in week 03 2019 (Table 2). At time of reporting data was not available for Northern Ireland.

Table 2: Excess mortality by UK country, for all ages

<table>
<thead>
<tr>
<th>Country</th>
<th>Excess detected in week 05 2019?</th>
<th>Weeks with excess in 2018/19</th>
</tr>
</thead>
<tbody>
<tr>
<td>England</td>
<td>×</td>
<td>NA</td>
</tr>
<tr>
<td>Wales</td>
<td>×</td>
<td>NA</td>
</tr>
<tr>
<td>Northern Ireland</td>
<td>NA</td>
<td>1</td>
</tr>
<tr>
<td>Scotland</td>
<td>×</td>
<td>52-2</td>
</tr>
</tbody>
</table>

*Excess mortality is calculated as the observed minus the expected number of deaths in weeks above threshold

* NA refers to data not available for this week

Figure 10: Weekly observed and expected number of all-age all-cause deaths, with the dominant circulating influenza A subtype, England, 2014 to week 05 2019
In week 05 2019, 56 samples tested positive for influenza (48 influenza A(H1N1)pdm09, 5 influenza A(H3) and 3 influenza A(not subtyped)) with a positivity of 50.5% through the UK GP sentinel schemes. 810 positive detections were recorded through the DataMart scheme (397 influenza A(H1N1)pdm09, 144 influenza A(H3), 268 influenza A(not subtyped) and 1 influenza B) with a positivity of 25.6%, this is above the baseline threshold of 9.2%.

Since week 40, a total of 427 samples (346 influenza A(H1N1)pdm09, 53 influenza A(H3), 22 influenza A(unknown subtype) and 6 influenza B) tested positive for influenza through this scheme.

**Sentinel swabbing schemes in England (RCGP) and the Devolved Administrations**

- In week 05 2019, 56 samples tested positive for influenza (48 influenza A(H1N1)pdm09, 5 influenza A(H3) and 3 influenza A(not subtyped)) with an overall positivity of 50.5% compared to 48.5% in week 04 2019 through the UK GP sentinel swabbing schemes (Figure 11).

Since week 40, a total of 427 samples (346 influenza A(H1N1)pdm09, 53 influenza A(H3), 22 influenza A(unknown subtype) and 6 influenza B) tested positive for influenza through this scheme.

**Respiratory DataMart System (England)**

- In week 05 2019, out of the 3,159 respiratory specimens reported through the Respiratory DataMart System, 810 samples (25.6%) were positive for influenza (397 influenza A(H1N1)pdm09, 144 influenza A(H3), 268 influenza A(not subtyped) and 1 influenza B) (Figure 12), which is above the MEM baseline threshold for this season of 9.2%. The highest positivity for influenza by age group was seen in the 15-44 year olds at 32.0% in week 05 (Figure 13).

The overall positivity for RSV continued to decrease from 3.3% in week 05 to 2.9% week 04 2019. Rhinovirus positivity increased slightly from 8.2% in week 04 to 9.0% in week 05 2019. Human metapneumovirus (hMPV) positivity continued to stabilise at 3.4%, following a small but increasing trend in positivity from week 40 2018 up to week 02 2019. Adenovirus and parainfluenza positivities remained low at 2.6% and 1.8% respectively (Figure 14).

*The Moving Epidemic Method has been adopted by the European Centre for Disease Prevention and Control to calculate thresholds for GP ILI consultations for the start of influenza activity in a standardised approach across Europe. The threshold to indicate a likelihood of influenza community circulation for Datamart % positive as calculated through the Moving Epidemic Method is 9.2% in 2018/19.*
- **Virus characterisation**

PHE characterises the properties of influenza viruses through one or more tests, including genome sequencing (genetic analysis) and haemagglutination inhibition (HI) assays (antigenic analysis). These data are used to compare how similar the currently circulating influenza viruses are to the strains included in seasonal influenza vaccines, and to monitor for changes in circulating influenza viruses. The interpretation of genetic and antigenic data sources is complex due to a number of factors, for example, not all viruses can be cultivated in sufficient quantity for antigen characterisation, so that viruses with sequence information may not be able to be antigenically characterised as well. Occasionally, this can lead to a biased view of the properties of circulating viruses, as the viruses which can be recovered and analysed antigenically, may not be fully representative of major variants, and genetic characterisation data does not always predict the antigenic characterisation.

The PHE Respiratory Virus Unit has characterised 397 influenza A(H1N1)pdm09 viruses detected since week 40. Genetic characterisation of 340 influenza A(H1N1)pdm09 viruses detected since week 40 shows that they all belong in the genetic subgroup 68.1, which was the predominant genetic subgroup in the 2017/18 season. One-hundred and ninety-six A(H1N1)pdm09 viruses have been antigenically characterised and are similar to the A/Michigan/45/2015-like Northern Hemisphere 2018/19 (H1N1)pdm09 vaccine strain.

Genetic characterisation of 45 A(H3N2) influenza viruses shows that they all belong to genetic subclade 3C.2a, with 42 belonging to a cluster within this genetic subclade designated as 3C.2a1. The Northern Hemisphere 2018/19 influenza A(H3N2) vaccine strain belongs in genetic subclade 3C.2a1.

Three influenza B viruses characterised to date, two influenza B viruses have been characterised where sequencing of the haemagglutinin (HA) gene shows they belong within genetic clade 1A of the B/Victoria lineage. One of them clusters in a subgroup characterised by deletion of two amino acids in the HA. The N.Hemisphere 2018/19 B/Victoria-lineage quardivalent and trivalent vaccine component virus (a B/Colorado/06/2017-like virus), is a double deletion subgroup virus. The other influenza B virus has been characterised genetically as belonging to genetic clade 3 of the B/Yamagata lineage and antigenically as similar to the B/Phuket/3073/2013 B/Yamagata lineage vaccine component in the N.Hemisphere 2018/19 quardivalent vaccine.

### Table 3: Viruses characterised by PHE Reference Laboratory, 2018/19

<table>
<thead>
<tr>
<th>Virus</th>
<th>No. viruses characterised</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Genetic and antigenic</td>
</tr>
<tr>
<td>A(H1N1)pdm09</td>
<td>139</td>
</tr>
<tr>
<td>A(H3N2)</td>
<td>0</td>
</tr>
<tr>
<td>B/Yamagata-lineage</td>
<td>1</td>
</tr>
<tr>
<td>B/Victoria-lineage</td>
<td>0</td>
</tr>
</tbody>
</table>

### Antiviral susceptibility

Influenza positive samples are screened for mutations in the virus neuraminidase gene known to confer oseltamivir and/or zanamivir resistance. Additionally, testing of influenza A(H1N1)pdm09, A(H3N2), and influenza B virus isolates for neuraminidase inhibitor susceptibility (oseltamivir and zanamivir) is performed at PHE-RVU using a functional assay. The data summarized below combine the results of both testing methods. The samples tested are routinely obtained for surveillance purposes, but diagnostic testing of patients suspected to be infected with neuraminidase inhibitor-resistant virus is also performed.

During the current 2018/19 season since week 40 2018, 280 influenza A(H1N1)pdm09 viruses have been tested for oseltamivir susceptibility. 271 were fully susceptible and 9 were resistant confirmed by PHE-RVU. All 9 oseltamivir resistant cases have the H275Y amino acid substitution. Six of the 9 cases are known to have received oseltamivir treatment. One case has no known exposure to oseltamivir. Two further cases remain under investigation.

231 out of the 291 influenza A(H1N1)pdm09 virus have also been tested for zanamivir susceptibility and all were susceptible. 36 influenza A(H3N2) viruses have been tested for oseltamivir susceptibility and for zanamivir susceptibility and all were susceptible to both agents. Three influenza B viruses have been tested for susceptibility for both oseltamivir and zanamivir and all were susceptible to both agents.

### Antimicrobial susceptibility

- Table 4 shows in the 12 weeks up to 03 February 2019, the proportion of all lower respiratory tract isolates of *Streptococcus pneumoniae*, *Haemophilus influenzae*, *Staphylococcus aureus*, MRSA and MSSA tested and susceptible to antibiotics. These organisms are the key causes of community acquired pneumonia (CAP) and the choice of antibiotics reflects the British Thoracic Society empirical guidelines for management of CAP in adults.

<table>
<thead>
<tr>
<th>Organism</th>
<th>Antibiotic</th>
<th>Specimens tested (N)</th>
<th>Specimens susceptible (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>S. pneumoniae</em></td>
<td>Penicillin</td>
<td>4139</td>
<td>88</td>
</tr>
<tr>
<td></td>
<td>Tetracycline</td>
<td>4457</td>
<td>86</td>
</tr>
<tr>
<td><em>H. influenzae</em></td>
<td>Amoxicillin/amoxicillin</td>
<td>16171</td>
<td>69</td>
</tr>
<tr>
<td></td>
<td>Co-amoxiclav</td>
<td>17471</td>
<td>85</td>
</tr>
<tr>
<td></td>
<td>Macrolides</td>
<td>3855</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Tetracycline</td>
<td>17492</td>
<td>98</td>
</tr>
<tr>
<td><em>S. aureus</em></td>
<td>Methicillin</td>
<td>6974</td>
<td>91</td>
</tr>
<tr>
<td></td>
<td>Macrolides</td>
<td>7782</td>
<td>65</td>
</tr>
<tr>
<td>MRSA</td>
<td>Clindamycin</td>
<td>427</td>
<td>44</td>
</tr>
<tr>
<td></td>
<td>Tetracycline</td>
<td>581</td>
<td>79</td>
</tr>
<tr>
<td>MSSA</td>
<td>Clindamycin</td>
<td>4432</td>
<td>76</td>
</tr>
<tr>
<td></td>
<td>Tetracycline</td>
<td>5881</td>
<td>93</td>
</tr>
</tbody>
</table>

*Macrolides = erythromycin, azithromycin and clarithromycin.*

7 of 12
- Up to week 04 2019, in 97.4% of GP practices reporting weekly to ImmForm, the provisional proportion of people in England who had received the 2018/19 influenza vaccine in targeted groups was as follows (Figure 15):
  - 46.7% in under 65 years in a clinical risk group
  - 44.8% in pregnant women
  - 71.2% in 65+ year olds

![Figure 15: Cumulative weekly influenza vaccine uptake by target group in England](image1.png)

- In 2018/19, all 2 and 3 year-olds continue to be eligible for flu vaccination, through their GPs.
  Up to week 04 2019, in 97.5% of GP practices reporting weekly to ImmForm, the provisional proportion of children in England who had received the 2018/19 influenza vaccine in targeted groups was as follows (Figure 16):
  - 43.0% in 2 year olds
  - 45.0% in 3 year olds

![Figure 16: Cumulative weekly influenza vaccine uptake by target group in England](image2.png)

- Provisional data from the third monthly collection of the influenza vaccine uptake by frontline healthcare workers show 65.8% were vaccinated by 31 December 2018 from 97.9% of all organisations, compared to 63.9% vaccinated in the previous season by 31 December 2017. The report provides uptake at national, NHS England local team and Trust-level.
• Provisional data from the third monthly collection of influenza vaccine uptake for children of school years Reception, 1, 2, 3, 4 and 5 age (from a sample of 94.8% of all Local Authorities in England) show the provisional proportion of children in England who received the 2018/19 influenza vaccine via school, pharmacy or GP practice by 31 December 2018 in targeted groups as follows:
  o 62.6% in children school year reception age (4-5 yrs) compared to 61.8% by 31 December 2017
  o 62.2% in children school year 1 age (5-6 yrs) compared to 60.0% by 31 December 2017
  o 60.3% in children school year 2 age (6-7 yrs) compared to 59.5% by 31 December 2017
  o 59.1% in children school year 3 age (7-8 yrs) compared to 56.7% by 31 December 2017
  o 56.9% in children school year 4 age (8-9 yrs) compared to 54.8% by 31 December 2017
  o 55.1% in children school year 5 age (9-10 yrs); age group not include in 2017/18 school vaccine programme.

International Situation

In the temperate zone of the Northern hemisphere, influenza activity continued to increase with influenza A(H1N1)pdm09 predominating overall. In the temperate zones of the Southern hemisphere, influenza activity returned to inter-seasonal levels. Worldwide, seasonal influenza subtype A viruses accounted for the majority of detections.

• Europe updated on 01 February 2019 (Joint ECDC-WHO Europe Influenza weekly update)

In week 04 2019, influenza activity continued to increase in the European Region. Influenza A virus detections dominated with A(H1N1)pdm09 viruses and A(H3N2) viruses co-circulating.

Of all the Member States and areas with influenza-like illness thresholds defined, countries in Eastern (Republic of Moldova, Russian Federation), Northern (Denmark, Estonia, Ireland, Latvia, Lithuania, Norway and UK (England)), Southern (Greece, Israel, Italy, Montenegro, Romania and Serbia) and Western (Belgium, Czech Republic, Luxemburg, Netherlands, Portugal, Spain and Switzerland) areas of the European region reported activity above baseline levels.

Of 45 Member States and areas reporting on intensity, 1 reported baseline (Kazakhstan), 22 reported low (across the region), 16 reported medium (across the region) and 6 reported high (Southern regions) intensity for week 04.

Of the 45 Member States reporting on geographic spread, 5 reported sporadic cases, 5 reported local spread, 9 reported regional spread (in Eastern, Southern and Western areas) and 26 reported widespread activity (across the region).

For week 04, 1,899 (51.3%) of the 3,704 sentinel specimens tested positive for influenza viruses, 1,880 (99%) were influenza A and 19 (1%) were influenza B. Of the 1,235 type A viruses subtyped, 716 (58%) were influenza A(H1N1)pdm09 and 519 (42%) were influenza A(H3N2). Of the 5 type B viruses ascribed to a lineage all were B-Yamagata.

For week 04, 439 laboratory-confirmed influenza cases were reported in ICUs, all of which were infected with influenza type A viruses. Among the 481 laboratory confirmed influenza cases in other wards reported 478 (99.4%) were infected with influenza type A viruses and 3 (0.6%) were infected with influenza type B viruses.

For week 04, 13,151 specimens from non-sentinel sources (such as hospitals, schools, primary care facilities not involved in sentinel surveillance, or nursing homes and other institutions) tested positive for influenza viruses. Of the 13,151, 13,074 (99.4%) were type A and 77 (0.6%) were type B viruses. Of the 4,010 influenza A viruses that were subtyped, 2,707 (67.5%) were A(H1N1)pdm09 and 1,304 (32.5%) were A(H3N2). No B viruses ascribed to a lineage

For week 04, data from the 23 Member States or areas reporting to the EuroMOMO project indicated excess mortality in adults and elderly populations overall. However, this result is driven by data from only a few countries.

• United States of America updated on 01 February 2019 (Centre for Disease Control report)

During week 04, influenza activity in the United States (US) increased. Influenza A and B viruses continue to co-circulate. Influenza A viruses have predominated since the start of the season with influenza A(H1N1)pdm09 predominating in most areas, however influenza A(H3) predominated in South-Eastern US.

A cumulative rate of 15.3 laboratory-confirmed influenza-associated hospitalisations per 100,000 population was reported, with the highest rate among those aged 65+ years old.
Nationwide during week 04, the proportion of outpatient visits for influenza-like illness (ILI) increased to 3.8% but remains above the national baseline of 2.2%.

For week 03, the proportion of deaths attributed to pneumonia and influenza (P&I) was 7.2%, at the epidemic threshold (7.2% for week 03) in the National Center for Health Statistics (NCHS) Mortality Surveillance System.

Two influenza-associated pediatric deaths (2 influenza A(not subtyped)) were reported to the CDC during week 04.

- **Canada** updated on 01 February 2019 (Public Health Agency report)

Overall, influenza continues to circulate across Canada with the Eastern region reporting higher levels of influenza activity than the Western region. At the national level, the influenza season appears to be past the peak of activity with most indicators showing stable or downward trends. Influenza A is the most common influenza virus circulating and the majority of these viruses are influenza A(H1N1)pdm09.

In week 04, a total of 2,270 laboratory confirmed detections of influenza were reported, of which 98% were influenza A. The percentage of tests positive for influenza from sentinel laboratories decreased to 20.7% in week 04, which is above the seasonal threshold of 5.0%.

In week 04, 1.8% of visits to healthcare professionals were due to ILI, the percentage of visits for ILI is within expected levels.

To date this season, 1,761 influenza-associated hospitalisations have been reported by participating provinces and territories, of which 1,755 (99.7%) were associated with influenza A. To date this season, 319 ICU admissions and 75 deaths have been reported; all but 1 reported deaths were associated with influenza A.

- **Global influenza update** updated on 04 February 2019 (WHO website)

In the temperate zone of the Northern hemisphere, influenza activity continued to increase with influenza A(H1N1)pdm09 predominating overall. In the temperate zones of the Southern hemisphere, influenza activity returned to inter-seasonal. Worldwide, seasonal influenza subtype A viruses accounted for the majority of detections.

In North America, influenza activity appeared to decrease slightly, with influenza A(H1N1)pdm09 predominating. In Canada, although positivity appeared to decrease, activity remained elevated in Eastern regions; paediatric hospitalisations remained elevated but within but within expected levels. In the United States, influenza activity appeared to have plateaued, with mainly influenza A(H1N1)pdm09 virus detected followed by influenza A(H3N2) viruses. Influenza-like illness (ILI) continued to be reported above the national baseline. In Mexico, an increase in influenza was reported with influenza A(H1N1)pdm09 most frequently detected

In Europe, influenza activity continued to increase across the continent with intensity mostly in the low-medium range. Although influenza A(H1N1)pdm09 was the most frequently detected virus overall, influenza A(H3N2) viruses co-circulated and predominated in some countries (Belgium, France, Luxemburg, Lithuania and Ukraine).

In In Central Asia, increased levels of severe acute respiratory infections (SARI) were reported. Influenza activity of predominantly influenza A(H1N1)pdm09 virus was reported in Kyrgyzstan.

In Northern Africa, decreased activity of predominantly influenza A(H3N2) viruses was reported in Egypt. In Morocco a sharp increase in influenza A(H1N1)pdm09 virus detection was reported.

In Western Asia, respiratory illness indicators along with influenza activity continued to increase in Armenia, Georgia, Israel and Turkey. Influenza A viruses predominated with A(H1N1)pdm09 in Armenia and Georgia and A(H3N2) in Israel and Turkey. In the Arabian Peninsula, appeared to decrease across reporting countries, with all seasonal subtypes co-circulating.

In East Asia, influenza activity continued to increase with influenza A(H1N1)pdm09 virus predominating. ILI activity increased in China and Hong Kong SAR and was reported at levels like that seen in the previous season. ILI levels and influenza A(H1N1)pdm09 detections decreased in Republic of Korea and appeared to have peaked in week 51. A sharp increase in influenza activity was reported in Mongolia with influenza A(H1N1)pdm09 virus predominantly detected.
In the Caribbean and Central American countries, influenza activity and RSV remained low across reporting countries with exception of Costa Rica, where increased detections of all seasonal influenza subtypes were reported.

In the tropical countries of South America, influenza and RSV activity were low in general.

In Western, Middle and Eastern Africa, Influenza virus detections were low across reporting countries. Influenza A(H3N2) viruses predominated followed by influenza B Victoria lineage virus.

In Southern Asia, influenza detections continued to increase with influenza A viruses predominating. In Afghanistan, influenza activity remained elevated, although influenza A(H1N1)pdm09 predominated, increased influenza A(H3N2) detections were reported in recent weeks. In India, increased detections of mainly influenza A(H1N1)pdm09 were reported. In Iran, influenza A(H3N2) virus predominated. There was an increase in detections in Pakistan with all seasonal influenza subtypes co-circulating.

In South-East Asia, influenza activity continued to be reported with all seasonal influenza subtypes co-circulating in the sub-region. Activity of predominantly influenza A(H1N1)pdm09 continued to be reported in Lao PDR, and was also reported in the Philippines along with influenza B-Victoria lineage. In Singapore, all seasonal influenza subypes were reported.

The WHO GISRS laboratories tested more than 232,136 specimens between 07 January 2019 and 20 January 2019. 59,457 were positive for influenza viruses, of which 58,436 (98.3%) were typed as influenza A and 1,021 (1.7%) as influenza B. Of the sub-typed influenza A viruses, 24,559 (77.7%) were influenza A (H1N1)pdm09 and 7,058 (22.3%) were influenza A (H3N2). Of the characterized B viruses, 85 (34.6%) belonged to the B-Yamagata lineage and 161 (65.4%) to the B-Victoria lineage.

- **Avian Influenza** latest update on 21 December 2019 (WHO website)

**Influenza A(H5) viruses**
Between **14 December 2018 and 21 January 2019**, no new laboratory-confirmed human cases of influenza A(H5) virus infections were reported to WHO.

According to reports received by the World Organization for Animal Health (OIE), various influenza A(H5) subtypes continue to be detected in birds in Africa, Europe and Asia.

**Influenza A(H7N9)**
Between **14 December 2018 and 21 January 2019**, no new laboratory-confirmed human cases of influenza A(H7N9) virus infection were reported to WHO. There have been no publicly available reports from animal health authorities in China of influenza A(H7N9) virus detections in animals in recent months.

**Influenza A(H9N2)**
Between **14 December 2018 and 21 January 2019**, 1 new laboratory-confirmed case of influenza A(H9N2) virus infection was reported to WHO from China. Avian influenza A(H9N2) viruses are enzootic in poultry in China

- **Middle East respiratory syndrome coronavirus (MERS-CoV)** latest update on 23 January 2019

Up to 03 February 2019, a total of five cases of Middle East respiratory syndrome coronavirus, MERS-CoV, (three imported and two linked cases) have been confirmed in the UK. On-going surveillance has identified 1,425 suspected cases in the UK that have been investigated for MERS-CoV and tested negative.

Between **01 December 2018 and 31 December 2018**, the National IHR Focal Point of The Kingdom of Saudi Arabia reported 5 additional cases of Middle East Respiratory Syndrome coronavirus(MERS-CoV).

Globally, since September 2012, WHO has been notified of 2,279 laboratory-confirmed cases of infection with MERS-CoV, including 806 related deaths. Further information on management and guidance of possible cases is available online. The latest ECDC MERS-CoV risk assessment can be found [here](#), where it is highlighted that risk of widespread transmission of MERS-CoV remains very low.
Acknowledgements

This report was prepared by the Influenza section, Immunisations and Countermeasures Division, National Infection Service, Public Health England. We are grateful to all who provided data for this report including the RCGP Research and Surveillance Centre, the PHE Real-time Syndromic Surveillance team, the PHE Respiratory Virus Unit, the PHE Modelling and Statistics unit, the PHE Dept. of Healthcare Associated Infection & Antimicrobial Resistance, PHE regional microbiology laboratories, Office for National Statistics, the Department of Health, Health Protection Scotland, National Public Health Service (Wales), the Public Health Agency Northern Ireland, the Northern Ireland Statistics and Research Agency, QSurveillance® and EMIS and EMIS practices contributing to the QSurveillance® database.

Related links

Sources of flu data
- Clinical surveillance through primary care in the UK
- Outbreak reporting
- FluSurvey
- MOSA
- Real time syndromic surveillance
- MEM threshold methodology paper and UK pilot paper

Disease severity and mortality data
- USISS system
- EuroMOMO mortality project

Vaccination
- Seasonal influenza vaccine programme (Department of Health Book)
- Childhood flu programme information for healthcare practitioners (Public Health England)
- 2018/19 Northern Hemisphere seasonal influenza vaccine recommendations (WHO)